Skip to main content
OpenTrials
Completed

NCT Number: NCT04851782

Effects of ivAED™ Device on "Air-in-line" Alarms and Workflow Disruption

The investigators propose to test the hypothesis, that is, the effectiveness of the ivAED to eliminate air-in-line, comparing two commercially available, standard IV infusion pumps: the Braun Infusomat® Space P and the Becton-Dickenson Alaris™ model 8100 pump (the latter is currently in use as the standard IV infusion pump at Keck Hospital of USC). Testing of an IV infusion pump other the Keck Hospital of USC standard is indicated, as the independent laboratory testing of the Alaris™ 8100 pump found that this model pump is prone to developing air bubbles as the infusion passes through the pump mechanism. These air bubbles can be sufficient to trigger the air-in-line alarm. The Braun Infusomat® Space P IV infusion pump is a market leader like the Alaris™ 8100 pump, was evaluated in independent testing with and without the ivAED™ device, and was NOT found to create bubbles.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

USC Keck Hospital

Los Angeles, California, 90033, United States

About this study

There are very few controlled human studies in the literature that assess various existing preventative measures for air embolism. After extensive, independent pre-clinical laboratory testing of the ivAED™ device demonstrating efficacy in removing air-in-line from IV infusions (see Appendix 1), this is the first-in-humans, clinical application of the ivAED™ device.

Testing of the ivAED™ device in patients is justified as that is the only means to determine the impact of the device on clinical IV infusion and nursing workflow disruptions (the primary outcomes of the study). Testing of the device in animals, or in healthy volunteers, or in computer simulations cannot provide this real-world information. In addition, the FDA typically requires that laboratory pre-clinical testing be coupled with clinical testing when applying for approval of new, investigational devices.

The investigators propose to test the hypothesis, that is, the effectiveness of the ivAED to eliminate air-in-line, comparing two commercially available, standard IV infusion pumps: the Braun Infusomat® Space P and the Becton-Dickenson Alaris™ model 8100 pump (the latter is currently in use as the standard IV infusion pump at Keck Hospital of USC). Testing of an IV infusion pump other the Keck Hospital of USC standard is indicated, as the independent laboratory testing of the Alaris™ 8100 pump found that this model pump is prone to developing air bubbles as the infusion passes through the pump mechanism. These air bubbles can be sufficient to trigger the air-in-line alarm. The Braun Infusomat® Space P IV infusion pump is a market leader like the Alaris™ 8100 pump, was evaluated in independent testing with and without the ivAED™ device, and was NOT found to create bubbles.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Surgical ICU patients that are receiving IV infusions
  • Patients or their surrogates have provided written, informed consent

Exclusion criteria

  • Patients who do not give consent to our researchers
  • Children (patients <18 years of age)
  • Pregnancy
  • Prisoners

Treatment and study plan

ivEAD tubing kit

Device

ivEAD tubing designed to reduce infusion pump alarms do to air in infusion line

Other names: Braun Infusomat Pump, Standard Infusion Pump

Primary outcomes

  1. Number of air-in-line IV infusion alarms (as detected by the IV infusion pump)

    Time frame: Patients will participate in the study from the time of enrollment in the ICU for up to 3 days

    Number of air-in-line IV infusion alarms (as detected by the IV infusion pump)

  2. Disruption of nursing workflow, measured as number of minutes required to attend to alarm and restore infusion flow.

    Time frame: Patients will participate in the study from the time of enrollment in the ICU for up to 3 days

    Disruption of nursing workflow, measured as number of minutes required to attend to alarm and restore infusion flow.

Secondary outcomes

  1. Cost

    Time frame: Patients will participate in the study from the time of enrollment in the ICU for up to 3 days

    Cost of disruption of nursing workflow, as measured by time-driven, activity-based costing

  2. Loss of Infusate

    Time frame: Patients will participate in the study from the time of enrollment in the ICU for up to 3 days

    Loss of infusate secondary to clearance of air in line

Sponsors and collaborators

Lead sponsor

Herrick Medical LLC

Industry

Collaborators

  • University of Southern California

Registry information

Official study title

Optimizing Value in Critical Care: Effect of Braun Infusomat®Space I IV Infusion Pump and ivEAD™ Air Elimination Device on "Air-in-line" Alarms and Workflow Disruption

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Apr 20, 2021
Registry last updated
Jul 11, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.